No Data
No Data
Quoin Pharmaceuticals To Carry Out 1-for-20 Reverse Stock Split On April 8th, 2025
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Buy Rating for Quoin Pharmaceuticals: Promising Phase 3 Trials and Strong Financial Position
Quoin Pharmaceuticals | 10-K: FY2024 Annual Report
Quoin Pharmaceuticals | 8-K: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
QUOIN PHARMACEUTICALS Earnings Results: $QNRX Reports Quarterly Earnings